• Inicio
• pct-off 70-90
• Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

4.6 (782) · € 9.50 · En stock

Toxicity and management in CAR T-cell therapy: Molecular Therapy - Oncolytics

Gut microbiome and CAR-T therapy, Experimental Hematology & Oncology

Da Volterra (@DaVolterra) / X

The heightened importance of the microbiome in cancer immunotherapy: Trends in Immunology

Cancers, Free Full-Text

The Discovery of Biomarkers in Cancer Immunotherapy - Computational and Structural Biotechnology Journal

Cancers, Free Full-Text

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. - Abstract - Europe PMC

Cancers, Free Full-Text

Frontiers Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Pharmacomicrobiomics: The universe of microbiome-drug interactions - Microbiome Times Magazine

Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies

Frontiers Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle